These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 15218328

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 8. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [Abstract] [Full Text] [Related]

  • 9. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD.
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [Abstract] [Full Text] [Related]

  • 10. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 11. Tacrolimus versus cyclosporine for adult lung transplant recipients: a meta-analysis.
    Fan Y, Xiao YB, Weng YG.
    Transplant Proc; 2009 Jun 15; 41(5):1821-4. PubMed ID: 19545736
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.
    Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J.
    Liver Transpl; 2006 May 15; 12(5):762-7. PubMed ID: 16528713
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rationale and design of the DIRECT study: a comparative assessment of the hyperglycemic effects of tacrolimus and cyclosporine following renal transplantation.
    Vincenti F, Rostaing L, DIRECT (Diabetes Incidence after REnal Transplantation: Neoral C2 monitoring versus Tacrolimus) investigators.
    Contemp Clin Trials; 2005 Feb 15; 26(1):17-24. PubMed ID: 15837449
    [Abstract] [Full Text] [Related]

  • 18. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.
    Beckebaum S, Klein C, Varghese J, Sotiropoulos GC, Saner F, Schmitz K, Gerken G, Paul A, Cicinnati VR.
    Aliment Pharmacol Ther; 2009 Oct 15; 30(8):834-42. PubMed ID: 19624550
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression.
    Martínez-Castelao A, Sarrias X, Bestard O, Gil-Vernet S, Serón D, Cruzado JM, Moreso F, Díez-Noguera A, Grinyó JM.
    Transplant Proc; 2005 Nov 15; 37(9):3788-90. PubMed ID: 16386539
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.